Canrenoate potassium

Cat. No.: HY-B1582A

CAS No.: 2181-04-6

Molecular Formula: $C_{22}H_{29}KO_4$

Molecular Weight: 396.56

Target: Mineralocorticoid Receptor

Pathway: Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Storage: 4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H_2O : 100 mg/mL (252.17 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.5217 mL	12.6084 mL	25.2169 mL
	5 mM	0.5043 mL	2.5217 mL	5.0434 mL
	10 mM	0.2522 mL	1.2608 mL	2.5217 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Canrenoate (Aldadiene) potassium, a proagent that releases canrenone, is a potent, competitive mineralocorticoid receptor (aldosterone receptor) antagonist. Potassium canrenoate, as a diuretic, is used for the research of hypertension[1][2][3].

In Vivo

Potassium canrenoate has been shown to cause in rats a dose-dependent increase in myelogenous leukemia and statistically significant increases in malignant tumor of the liver, thyroid, brain and mammary gland[2][3].

Potassium canrenoate (20 mg/kg/day; drinking water) reduces isoprenaline-induced cardiac fibrosis in the rat[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Iqbal J, Andrew R, et al. Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist. J Clin Endocrinol Metab. 2014;99(3):915-922.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA